Predictive Oncology Management

Management criteria checks 0/4

Predictive Oncology's CEO is Raymond Vennare, appointed in Nov 2022, has a tenure of less than a year. total yearly compensation is $638.58K, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth €40.14K. The average tenure of the management team and the board of directors is 1.4 years and 2.4 years respectively.

Key information

Raymond Vennare

Chief executive officer

US$638.6k

Total compensation

CEO salary percentage	13.7%
CEO tenure	less than a year
CEO ownership	0.2%
Management average tenure	1.4yrs
Board average tenure	2.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Raymond Vennare's remuneration changed compared to Predictive Oncology's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$639k	US$88k	-US$26m
Sep 30 2022	n/a	n/a	-US$26m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$33k	n/a	-US$20m

Compensation vs Market: Raymond's total compensation ($USD638.58K) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Raymond's compensation has increased whilst the company is unprofitable.

CEO

Raymond Vennare (70 yo)

less than a year

Tenure

US$638,578

Compensation

Mr. Raymond F. Vennare is Chief Executive Officer and Chairman at Predictive Oncology Inc. from November 01, 2022. He Co-Founded ThermalTherapeutic Systems, Inc. in 2006 and served as its Executive Vice Pr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Raymond Vennare	CEO & Chairman	less than a year	US$638.58k	0.18% $ 40.1k
Robert Myers	CFO & Secretary	11.6yrs	US$511.87k	0.089% $ 20.1k
Theresa Ferguson	Senior Director of Marketing	1.3yrs	no data	no data
Pamela Bush	Chief Business Officer	1.6yrs	no data	0.059% $ 13.4k
Lawrence DeLucas	Senior Vice President of Biologics	no data	no data	no data
Arlette Uihlein	Senior VP of Translational Medicine & Drug Discovery and Medical Director	no data	no data	no data

1.4yrs

Average Tenure

68yo

Average Age

Experienced Management: S1K's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Raymond Vennare	CEO & Chairman	1.8yrs	US$638.58k	0.18% $ 40.1k
Bernard Harris	Member of Business Advisory Board	less than a year	no data	no data
Charles Nuzum	Lead Independent Director	3yrs	US$140.56k	no data
Andrew Einhorn	Member of Business Advisory Board	less than a year	no data	no data
Veena Rao-Mirmira	Director	less than a year	no data	0.099% $ 22.4k
Marc Malandro	Member of Scientific Advisory Board	4.8yrs	no data	no data
Daniel Handley	Independent Director	3.4yrs	US$73.89k	0.32% $ 72.1k
Robert Murphy	Member of Scientific Advisory Board	4.8yrs	no data	no data
Matthew Hawryluk	Director	less than a year	US$8.33k	0.13% $ 29.6k
Nancy Chung-Welch	Independent Director	3yrs	US$118.34k	0.38% $ 85.0k
Gregory St. Clair	Independent Director	3yrs	US$85.00k	0.40% $ 90.5k
Christoph Reinhard	Member of Scientific Advisory Board	less than a year	no data	no data

2.4yrs

Average Tenure

63yo

Average Age

Experienced Board: S1K's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Predictive Oncology Management

Management criteria checks 0/4

Key information

Recent management updates

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Predictive Oncology Inc. Announces Executive Changes

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

High number of new and inexperienced directors

Recent updates

Predictive Oncology Inc. Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery

Predictive Oncology Inc. Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Predictive Oncology Inc. has filed a Follow-on Equity Offering in the amount of $3.696 million.

Predictive Oncology Inc. to Report Q1, 2024 Results on May 15, 2024

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Predictive Oncology Inc. to Report Q3, 2023 Results on Nov 14, 2023

Predictive Oncology Inc. Announces Executive Changes

Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Predictive Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

Predictive Oncology Inc. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in FY 2021)

Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer

Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Board

Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company's Scientific Advisory Board

Predictive Oncology Appoints Matthew J. Hawryluk Ph.D. to the Board of Directors

Third quarter 2022 earnings released: US$0.052 loss per share (vs US$0.083 loss in 3Q 2021)

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Appoints David S. Smith to the Company's Board of Directors

Predictive Oncology Appoints Raymond F. Vennare as Chief Executive Officer Effective November 1, 2022

Predictive Oncology Inc., Annual General Meeting, Dec 01, 2022

Predictive Oncology Inc. Announces Retirement of J. Melville (“Mel”) Engle as Chairman and A Member of Board of Directors

Second quarter 2022 earnings released: US$0.075 loss per share (vs US$0.05 loss in 2Q 2021)

Predictive Oncology Inc. Announces Unaudited Consolidated Impairment Charges for the Three Months Ended June 30, 2022

Predictive Oncology Appoints Julia Kirshner as Chief Scientific Officer, Effective August 1, 2022

Predictive Oncology Inc. Announces Christina Jenkins Intends to Resign as Director, Effective August 31, 2022

Insider recently bought €59k worth of stock

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings released: US$0.051 loss per share (vs US$0.11 loss in 1Q 2021)

Predictive Oncology Inc. Appoints Theresa Ferguson as Senior Director of Marketing

Full year 2021 earnings released: US$0.36 loss per share (vs US$2.21 loss in FY 2020)

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Inc. Reports Strong Results from Its AA Cancer Drug Evaluation

High number of new directors

Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million.

Third quarter 2021 earnings released: US$0.083 loss per share (vs US$0.46 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.36 loss in 2Q 2020)

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.93 loss in 1Q 2020)

Director has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$6.86 loss in FY 2019)

Predictive Oncology’S, Skyline Medical Division, Developing Generation 3 Direct-To-Drain Automated Fluid Waste Management System

Predictive Oncology Inc. Completes Key Data Generation Milestones in Its Retrospective Study

Predictive Oncology Inc. announced that it expects to receive $17.635344 million in funding

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $7.389004 million.

New 90-day high: €1.30

Predictive Oncology Announces the Start of Its Drug Repurposing Project Using Its Ground-Breaking Pedal™ Platform for Ovarian Cancer

Predictive Oncology Regains Compliance with Nasdaq Minimum Bid Price Requirement

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $4.097964 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $2.2 million.

New 90-day high: €0.89

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $3.074007 million.

New 90-day high: €0.73

Third quarter 2020 earnings released: US$0.46 loss per share

New 90-day low: €0.49

Predictive Oncology Receives A Letter from the Listing Qualifications Department Nasdaq Stock Market

Predictive Oncology Inc. announced that it has received $1.370002 million in funding

Precision Therapeutics Inc. Announces Executive Appointments

New 90-day low: €0.61

Predictive Oncology Inc. (NasdaqCM:POAI) completed the acquisition of Assets of Quantitative Medicine, LLC for $2.6 million.

Predictive Oncology Inc. (NasdaqCM:POAI) entered into a letter of intent to acquire Assets of Quantitative Medicine, LLC.

Predictive Oncology Secures License for an Additional 71 Unique Ovarian Cancer Cell Lines from Ximbio

New 90-day low - €0.77

New 90-day low - €1.12

Earnings released

CEO Compensation Analysis